Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06542250
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-29
Brief Title:
A Study to Evaluate Safety PK PD and Efficacy of AZD5492 a T Cell-engaging Antibody Targeting CD20 in Subjects With RR B-Cell Malignancies
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Modular Phase III Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of AZD5492 a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TITANium
Brief Summary:
This is a Phase III study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None